Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1
SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages2 for the one in 50 Americans at risk for anaphylaxis3
Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2019-07-09 02:00:002019-07-09 02:00:00Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine
